How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,088 results for

Depo Provera

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection Full Text available with Trip Pro

Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection Depot medroxyprogesterone acetate (Depo-Provera) has been associated with an increased risk of HIV acquisition. In a longitudinal study, we investigated the impact of Depo-Provera use by healthy women on expression of immune markers for HIV preference and on HIV infection ex vivo at baseline (visit 1), one month (visit 2) and three (...) months (visit 3) after Depo-Provera treatment. We found a significant increase in the frequency and expression of integrin α4β7 on CD4+ T cells at visit 2. Interestingly, Hispanic but not black women exhibited a significant increase in integrin α4β7 cell numbers and expression levels at visit 2, whereas, black but not Hispanic women exhibited a significant change in CCR5 and CD38 expression levels between visit 2 and visit 3. The frequency of terminal effector memory CD4+ T cells decreased

2017 ImmunoHorizons

142. Uptake of long-acting reversible contraceptive devices in Western region of The Gambia Full Text available with Trip Pro

based cross-sectional study of women attending family planning clinic were studied using intervieweradministered questionnaire which included information on socio-demographic factors, reproductive health and contraceptive use of the participants.About 89 % of study participants used long acting reversible contraceptive methods. Of the three commonly available long acting reversible contraceptive methods, Depo Provera was the most commonly used method; 78 of 141 (55.32%); followed by implants (43.3 (...) %) and intrauterine contraceptive (1.42%). Being housewives, with 3-4 living children and having secondary level education were associated with high uptake of LARC.The uptake of long acting reversible contraceptive was high; with Depo Provera as the most commonly used contraceptive method in The Gambia. There seemed to be an increase in the uptake of implants; with intrauterine contraceptive device being the least commonly used method.

2017 African health sciences

143. Hypoglycemia and the Gut Microbiome

pint of whole blood) within the past 2 months; Active alcohol abuse or substance abuse; Current administration of oral or parenteral corticosteroids; Pregnancy and/ or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant

2017 Clinical Trials

144. Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

if consistently employed as the patient's preferred and usual lifestyle , sex only with person of the same sex, sex only with vasectomised partner, medroxyprogesterone injections [e.g., Depo-Provera], levonorgestrel intrauterine system [e.g., Mirena], intrauterine device (IUD), or barrier method [e.g., condom, diaphragm] for the duration of the study and for 6 months after the last dose of CT7001. The drug-drug interactions of CT7001 are not fully characterised so contraceptives that are prone to drug-drug

2017 Clinical Trials

145. Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

injections (e.g. Depo-provera), copper-banded intra-uterine devices, hormone-impregnated intra-uterine systems and vasectomised partners; all methods of contraception, with the exception of total abstinence, should be used in combination with the use of a condom by male sexual partners). Known hypersensitivity or any contraindications to the trial drugs, including nab-paclitaxel/nintedanib, to their excipients or to contrast media or other ingredients including peanuts and soya. Patients unable to comply

2017 Clinical Trials

146. Safety, PK, and PD Study of IVRs Releasing TFV and LNG

had at least two spontaneous menses since pregnancy outcome Use of any hormonal contraceptive method in the last 3 months (oral, transdermal, transvaginal, implant, or hormonal intrauterine contraceptive device) Injection of Depo-Provera in the last 10 months Use of copper IUD Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study History of sensitivity/allergy to any component of the study products, topical anesthetic

2017 Clinical Trials

147. Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

, hysterectomy, removal of the uterus, bilateral oophorectomy, removal of both ovaries) at least 6 months before dosing) or one year post menopausal), abstinent or using adequate contraceptive precautions (eg, intrauterine contraceptive device; oral contraceptives; diaphragm, cervical cap, or condom in combination with contraceptive jelly, cream or foam; Norplant® or Depo-Provera®) from 3 months prior to this study through 56 days after challenge A negative pregnancy test at the time of enrollment Free

2017 Clinical Trials

148. Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea

instructional guide (e.g., spicy foods, thermally hot foods and drinks, hot environments, prolonged sun exposure, strong winds and alcoholic beverages). Non-nursing, female subjects of child bearing potential, who are using an acceptable form of birth control: total abstinence, oral (birth control pills), intravaginal: (e.g. NuvaRing®), implantable (e.g. Norplant®), injectable (e.g. Depo-Provera®) or transdermal (e.g. Ortho Evra®) contraception; intrauterine device (IUD); double-barrier (diaphragm or condom (...) , Valergen, Depo-Testadiol, Depogen, birth control pills), for less than 2 months prior to the Baseline Visit. (Subjects using estrogens for 2 months or more are not excluded unless the subject expected to change dose, drug, or discontinue estrogen use during the study). Use within 2 month prior to the Baseline Visit of 1) topical retinoids to the face, 2) systemic antibiotics known to have an impact on the severity of facial rosacea (e.g., containing tetracycline and its derivatives, erythromycin

2017 Clinical Trials

149. Feasibility of Outpatient Closed Loop Control With the Bionic Pancreas in Cystic Fibrosis Related Diabetes

the study. Acceptable contraception methods include: Oral contraceptive pill (OCP) Intrauterine Device (IUD, hormonal or copper) Male condoms Female condoms Diaphragm or cervical cap with spermicide Contraceptive patch (such as OrthoEvra) Contraceptive implant (such as Implanon, Nexplanon) Vaginal ring (such as NuvaRing) Progestin shot (such as Depo-Provera) Male partner with a vasectomy proven to be effective by semen analysis Need to go outside of the designated geographic boundaries during the study

2017 Clinical Trials

150. Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

with spermicide, Contraceptive patch (such as OrthoEvra), Contraceptive implant (such as Implanon, Nexplanon), Vaginal ring (such as NuvaRing), Progestin shot (such as Depo-Provera), Male partner with a vasectomy proven to be effective by semen analysis Current alcohol abuse (intake averaging > 3 drinks daily in last 30 days) or other substance abuse (use within the last 6 months of controlled substances other than marijuana without a prescription) Unwilling or unable or to avoid use of drugs that may dull

2017 Clinical Trials

151. Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

) Exclusion Criteria: Has not reached menarche Menopause: natural or induced by surgical/medical treatment Pregnant or breasfeeding Female or her male partner refuses to use barrier method of birth control (for sexually active) Current use of any of the following contraceptives (copper IUD, oral combined, Progestin-only including but not limited to: Provera, Aygestin, Nexplanon, Implanon, Depo Provera, Mirena IUD) VWF:Ag or VWF:RCo <40% Diagnosis of a qualitative platelet disorder Personal history

2017 Clinical Trials

152. A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Patients With Rosacea

ring (NuvaRing®), Depo-Provera® (Medroxy progesterone acetate), double barrier methods (e.g., condom and spermicide), or intrauterine device; Female subjects of child bearing potential had to have a negative urine pregnancy test at baseline; Subjects who used make-up had to have used the same brands/types of make-up for a minimum period of 14 days prior to study entry and had to agree to use the same make-up, brand/type, or frequency of use, throughout the study. Exclusion Criteria: Pregnant

2017 Clinical Trials

153. AMP002 Phase III Contraceptive Study

breastfeeding, she must have demonstrated return to regular cycling and have had at least three consecutive, spontaneous menses post lactation prior to the date of consent. If the subject received prior administration of injectable contraceptives (e.g., depot-medroxyprogesterone acetate [DMPA], Depo Provera), there must be at least 10 months since the last injection and the subject must have had at least two consecutive, spontaneous menses prior to the date of consent. If a contraceptive implant

2017 Clinical Trials

154. Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis

of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), Essure® permanent birth control, and abstinence with a documented second acceptable method of birth control if the subject becomes sexually active. Exclusion Criteria: Females who are pregnant, breastfeeding, intending

2017 Clinical Trials

155. Modifiers of Tenofovir in the Female Genital Tract

): University of Minnesota - Clinical and Translational Science Institute Study Details Study Description Go to Brief Summary: Two-armed, single visit, pharmacokinetic study to compare tenofovir diphosphate concentrations in cervical tissues of women on Depo-Provera contraception vs non-hormonal contraception. Condition or disease Intervention/treatment HIV/AIDS Contraception Drug: Tenofovir Disoproxil Fumarate Drug: Depo-Provera Study Design Go to Layout table for study information Study Type (...) : Observational Actual Enrollment : 50 participants Observational Model: Case-Control Time Perspective: Cross-Sectional Official Title: Modifiers of Tenofovir Exposure in the Female Genital Tract of African Women on Depo-provera Actual Study Start Date : November 17, 2017 Actual Primary Completion Date : March 29, 2018 Actual Study Completion Date : April 2, 2018 Resource links provided by the National Library of Medicine related topics: available for: Groups and Cohorts Go to Group/Cohort Intervention

2017 Clinical Trials

156. The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea

opinion, may interfere with study participation. Women of childbearing potential must be willing to use a form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant(R), Depo-Provera(R) double barrier methods (e.g., condom and spermacide) and abstinence. Subjects must provide written informed consent. Willingness to comply with the study design and procedures. Subjects who agree to sign

2017 Clinical Trials

157. A Pilot Study of Fear Extinction Learning in Anxious Youth

the previous 2 years (at least 10 treatment sessions over a period of less than 1 year conducted by a licensed provider of CBT) Child has a major neurological disorder, a major medical illness or hearing impairment that requires a prohibited episodic or chronic systemic medication or that would interfere Child is pregnant as indicated by history or a positive pregnancy test at Gate B. Sexually active girls must agree to use an effective form of birth control, either hormonal (BCP, Depo-Provera or Norplant

2017 Clinical Trials

158. Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

between days 21-24. Procedure: Hysterectomy Undergo hysterectomy Other: Laboratory Biomarker Analysis Correlative studies Drug: Medroxyprogesterone Acetate Given IM Other Names: Amen Aragest Ciclotal Clinofem Clinovir Cycrin Depo-Clinovir Depo-Provera Depot-Medroxyprogestereone Acetate Farlutal G-Farlutal Gestapuran Hysron Lutoral Medroxyprogesterone 17-Acetate Medroxyprogesteroni Acetas Methylacetoxyprogesterone Metipregnone MPA Nadigest Nadigest (vet) Nidaxin Nidaxin (vet) Oragest Perlutex Prodasone (...) Aragest Ciclotal Clinofem Clinovir Cycrin Depo-Clinovir Depo-Provera Depot-Medroxyprogestereone Acetate Farlutal G-Farlutal Gestapuran Hysron Lutoral Medroxyprogesterone 17-Acetate Medroxyprogesteroni Acetas Methylacetoxyprogesterone Metipregnone MPA Nadigest Nadigest (vet) Nidaxin Nidaxin (vet) Oragest Perlutex Prodasone Provera Sodelut G Veramix Outcome Measures Go to Primary Outcome Measures : Mean post-treatment tumor progesterone receptor score [ Time Frame: Up to 3 years ] The percent cells

2017 Clinical Trials

159. The Effect of a High Protein, High Fiber Dietary Supplement on Weight and Fat Loss

), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) for at least 3 months Double-barrier method Non-hormonal IUDs Hormonal IUD methods must be a stable dose for at least 3 months Vasectomy of partner Non-heterosexual lifestyle A BMI between 27.0 - <35.0 kg/m2 (inclusive). Subjects must meet exactly the inclusion BMI at screening, or be screen failed. Subjects who meet the BMI requirement at screening and present at run-in with a BMI of <27.0 or >35 kg/m2

2017 Clinical Trials

160. Post-Prandial Liver Glucose Metabolism in PCOS

. For non-PCOS groups: regular menstrual cycles at least 1.5 years after menarche, and no clinical evidence of hyperandrogenism. Exclusion Criteria: Use of medications known to affect insulin sensitivity: oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, HIV medications. Nexplanon, Depo-Provera or Mirena progesterone only contraceptives. Dermal patch or vaginal ring contraception methods. For controls only: metformin or oral contraception. Currently pregnant

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>